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Rationale: Acquired diaphragm muscle weakness is a key feature in
several chronic conditions, including chronic obstructive pulmonary
disease, congestive heart failure, and difficult weaning frommechan-
ical ventilation. No drugs are available to improve respiratory muscle
function in these patients. Recently, we have shown that the calcium
sensitizer levosimendan enhances the force-generating capacity of
isolated diaphragm fibers.
Objectives: To investigate the effects of the calcium sensitizer levosi-
mendan on in vivo human diaphragm function.
Methods: In a double-blind, randomized, crossover design, 30 healthy
subjects performed two identical inspiratory loading tasks. After the
first loading task, subjects received levosimendan (40 mg/kg bolus
followedby0.1/0.2mg/kg/mincontinuous infusion)orplacebo.Trans-
diaphragmatic pressure, diaphragm electrical activity, and their rela-
tionship (neuromechanical efficiency)weremeasuredduring loading.
Magnetic phrenic nerve stimulation was performed before the first
loading task and after bolus administration to assess twitch contractil-
ity. Center frequency of diaphragmelectrical activity was evaluated to
study the effects of levosimendanonmuscle fiber conduction velocity.
Measurements andMain Results: Theplacebogroup showeda9%(P¼
0.01) loss of twitch contractility after loaded breathing, whereas no
loss in contractilitywas observed in the levosimendangroup.Neuro-
mechanical efficiency of the diaphragmduring loading improvedby
21% (P , 0.05) in the levosimendan group. Baseline center fre-
quencyofdiaphragmelectrical activitywas reducedafter levosimen-
dan administration (P, 0.05).
Conclusions: The calcium sensitizer levosimendan improves neuro-
mechanical efficiency and contractile function of the human dia-
phragm.Ourfindingssuggest anewtherapeutic approach to improve
respiratory muscle function in patients with respiratory failure.
Keywords: diaphragm; muscle weakness; calcium sensitization;
levosimendan
Impaired force generation of the respiratory muscles has been
recognized in a variety of diseases, including chronic obstructive
pulmonary disease (COPD) and congestive heart failure, and in
critically ill patients (1–7). The pathophysiological substrate of
diaphragm dysfunction in these disorders is multifactorial and
includes muscle fiber atrophy and contractile protein dysfunction
(3, 8–11). We found that diaphragm muscle fibers of patients with
COPD display reduced sensitivity of the contractile proteins to
calcium (9, 12). In other words, more calcium is needed to develop
the same amount of force as in the non-COPD diaphragm, result-
ing in impaired contractile efficiency of the diaphragm muscle.
Subsequent studies have shown that calcium sensitivity is also
reduced in the diaphragm of animal models of congestive heart
failure and prolonged mechanical ventilation (2, 13). Despite
a better understanding of respiratory muscle dysfunction in
chronic diseases, no drug is available to improve respiratory mus-
cle function in humans.
Levosimendan is a clinically used calcium sensitizer that has
been approved to enhance cardiac contractility in patients with
acute heart failure. Clinical studies have shown that levosimendan
improves cardiac function in these patients (14). Levosimendan
enhances the binding of calcium to troponin C, thereby improv-
ing the responsiveness of myofilaments to calcium. Accordingly,
a greater amount of force is generated for the same level of cyto-
solic calcium, resulting in enhanced contractile efficiency. Levo-
simendan has vasodilatory properties mediated by the opening of
the ATP-sensitive potassium (KATP) channels (15).
Recently, we have shown that levosimendan enhances calcium
sensitivity of permeabilized muscle fibers obtained from the hu-
man diaphragm, including patients with COPD (12). However,
the effects of calcium sensitizing on the human diaphragm in
vivo have not been studied. Based on our in vitro data (12), we
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Respiratory muscle weakness frequently occurs in chronic
diseases and contributes to morbidity and mortality. There
is no specific pharmacological treatment available to im-
prove respiratory muscle function in patients with impeding
respiratory muscle failure. Previous studies have demon-
strated that calcium sensitizers improve in vitro function of
the respiratory muscles.
What This Study Adds to the Field
We report that the calcium sensitizer levosimendan improves
neuromechanical efficiency of the human diaphragm. In ad-
dition, levosimendan restored the loss of diaphragm con-
tractility after an intervention of loaded breathing. These
findings suggest that levosimendan treatment may be an ef-
fective strategy to improve muscle function in patients with
respiratory muscle weakness.
hypothesize that levosimendan improves contractile function of
the human diaphragm in vivo through calcium sensitizing and
that levosimendan would decrease muscle fiber conduction veloc-
ity of the diaphragm through its effects on KATP channels in
diaphragm fibers. We tested this hypothesis in a double-blind,
placebo–controlled, crossover design in healthy subjects perform-
ing inspiratory loading tasks. Some of the results of this study
have been previously reported in the form of an abstract (16).
METHODS
We enrolled 30 healthy volunteers in this trial. The protocol was ap-
proved by the ethical committee of the Radboud University Nijmegen
Medical Centre and registered at ClinicalTrials.gov (NCT01101620).
All subjects gave their informed consent.
Esophageal Catheter
Diaphragm electromyographic activity (EMGdi), esophageal pressure
(Pes), and gastric pressure (Pga) were obtained with a multielectrode
esophageal catheter with two balloons (details are provided in the on-
line supplement). Transdiaphragmatic pressure (Pdi) was calculated as
Pga 2 Pes.
Magnetic Stimulation and Maximal Inspiratory Effort
Cervical magnetic stimulation of the phrenic nerves was performed to
measure twitch Pdi (Pditw) and compound muscle action potential of
the diaphragm (CMAPdi). Details about the stimulation protocol are
provided in the online supplement.
Maximal voluntary Pdi (Pdimax) was measured as mean Pdi in the
first second during a maximal inspiratory effort against a closed valve
at functional residual capacity.
Inspiratory Loading Task
Each subject performed two identical loading tasks, one before and one
after administration of the study medication. Sitting in upright position
with uncast abdomen, subjects breathed through a mouthpiece while
wearing a nose clip. Subjects performed intermittent inspiratory maneu-
vers of 10 seconds against a closed valve (near-isometric contractions)
followed by 7 seconds of unloaded breathing. Duty cycle was imposed by
a sound signal, and subjects were asked to target 40% of Pdimax. Visual
feedback of Pdi was provided. Total loading task duration was 10
minutes. During loading, EMGdi and Pdi were recorded continuously,
as well as in unloaded conditions approximately 5 minutes before and
after loading. Respiratory effort sensation was scored with a Borg scale
(range, 6–20) at 1, 3, 6, and 9 minutes into loading.
Experimental Protocol
The protocol is presented in Figure 1. Pditw and Pdimax were measured and
followed by the first loading task and 30 minutes of unloaded breathing.
After randomization, subjects received levosimendan bolus (40 mg/kg
bodyweight, intravenously) or an equal volume of placebo in 10 minutes.
Pditw and Pdimax measurements were repeated and followed by 30 minutes
of continuous levosimendan (0.1 mg/kg bodyweight/min, intravenously) or
placebo infusion. A second loading task was performed while infusing
levosimendan (0.2 mg/kg/min, intravenously) or placebo.
Heart rate, end tidal carbon dioxide (etCO2), and peripheral oxygen
saturation (SpO2) were monitored continuously. Blood pressure was
measured noninvasively every 10 minutes and during bolus administra-
tion each minute. In six subjects, cardiac output was determined
by transthoracic echocardiography directly before and after bolus
administration.
Data Analysis and Statistics
Measurement variables were analyzed offline in Matlab R2009b
(The Mathworks, Natick, MA) (details are provided in the online sup-
plement). The ratio of mean inspiratory Pdi and EMGdi amplitude
was calculated as a measure of the neuromechanical efficiency of the
diaphragm. Changes in muscle fiber conduction velocity were evaluated
using the power spectrum center frequency (CFdi) of the EMGdi (details
are provided in the online supplement). Comparisons were made with
the appropriate t test. Changes over time during loaded breathing were
analyzed using repeated measures ANOVA. Values are means6 SEM,
and P , 0.05 was considered significant. Statistical analyses were per-
formed with SPSS 16.0 (SPSS, Chicago, IL).
RESULTS
Baseline characteristics of the subjects (male/female, 23/7; age,
22 6 0.4 yr; bodyweight, 74 6 1 kg; and body mass index, 23 6
0.4 kg/m2) were not different between the placebo and levosi-
mendan groups. All subjects (n ¼ 30) received study medication
as dictated by the protocol. One subject was excluded due to
technical problems with the esophageal catheter. Two subjects
were not able to maintain targeted Pdi (, 30% of Pdimax) dur-
ing the first loading task and were excluded from data analysis.
The remaining subjects (placebo, n ¼ 13; levosimendan, n ¼ 14)
were able to keep their targeted Pdi during both loading tasks
(44 6 1% and 43 6 2%), indicating compliance to the protocol.
SpO2 was above 96% in all subjects during the study; no supple-
mental oxygen was given. There were no differences in etCO2
between the placebo and levosimendan group during loaded
breathing.
Furthermore, there were no serious adverse events during the
experimental protocol. One subject, receiving levosimendan, ex-
perienced a mild degree of nausea after completion of the study.
Diaphragm Contractility
Cervical magnetic stimulation of the phrenic nerves resulted in
reproducible twitch pressures in all subjects. Data frommagnetic
stimulation and maximal inspiratory maneuvers, as well as he-
modynamic data, are given in Table 1. There was no significant
difference in Pditw and Pdimax between the placebo and the
levosimendan groups before study medication.
Figure 2 shows a decreased contractile response of the dia-
phragm after the first loading task in a subject receiving placebo.
Figure 1. Schematic description of the protocol. Pdimax ¼ maximum
transdiaphragmatic pressure; Pditw¼ twitch transdiaphragmatic pressure.
Doorduin, Sinderby, Beck, et al.: Levosimendan Improves Diaphragm Function 91
On average, loaded breathing in subjects receiving placebo
resulted in significant reductions in Pditw (29 6 3%; P ¼ 0.01)
and Pdimax (25 6 3%; P , 0.05). The group receiving levosi-
mendan after the first period of loaded breathing revealed no
significant decrease in Pditw and Pdimax (Figure 3; Table 1).
Neuromechanical Efficiency of the Diaphragm
In Figure 4, representative tracings of EMGdi and Pdi are pre-
sented for the first loading task (before study medication) and the
second loaded task (with study medication) for both groups.
Neuromechanical efficiency of the diaphragm (Pdi/EMGdi) in
the first loading task was not different between the placebo and
the levosimendan groups (both 1.3 6 0.2 cm H2O/mV) and
remained stable throughout the loading task (Figure 5). Neuro-
mechanical efficiency during unloaded breathing and during the
second loading task was improved by 21% (P , 0.05, compared
with the first loading task) in the levosimendan group, whereas
neuromechanical efficiency was not affected in the placebo group
(Figure 5). The improved neuromechanical efficiency in subjects
receiving levosimendan sustained throughout the entire loading
task.
Center Frequency of Diaphragm Electrical Activity
During both loaded breathing protocols, CFdi decreased over time
(P , 0.001) (see Figure E1 in the online supplement) in both
groups. Administration of levosimendan resulted in a downward
shift in baseline CFdi during the second loaded breathing proto-
col (P , 0.05; Figure E1), whereas placebo did not affect CFdi.
Respiratory Effort Sensation
Respiratory effort sensation increased over time (P , 0.001)
during loaded breathing until a score of 16 was reached. Neither
levosimendan nor placebo affected respiratory effort sensation.
DISCUSSION
The present study is the first to evaluate the effect of the calcium
sensitizer levosimendan on human diaphragm function in vivo.
In this double-blind, randomized study, an intervention of loaded
breathing resulted in significant loss of diaphragm contractility in
the placebo group but not in the levosimendan group, suggesting
that levosimendan restored diaphragm contractility. Loaded
breathing after drug administration was associated with im-
proved neuromechanical efficiency of the diaphragm in the lev-
osimendan group. Furthermore, levosimendan reduced baseline
center frequency of diaphragm electrical activity. Levosimendan
was well tolerated with negligible side effects.
Calcium Sensitivity and Muscle Fiber Conduction Velocity:
Effects of Levosimendan
Skeletal muscle force develops as intracellular calcium rises and
binds to troponin C, resulting in conformational changes in the
troponin complex, allowing interaction between actin andmyosin
to form force-generating cross-bridges. Reuptake of calcium from
the cytoplasm into the sarcoplasmic reticulum is a high energy–
consuming process (up to 40% of total energy expenditure).
Thus, reduced sensitivity of the troponin complex for calcium
requires higher levels of cytoplasmic calcium to generate the
same amount of force, requiring higher energy consumption and
elevated CO2 production.
Levosimendan belongs to a relatively new class of drugs, the
calcium sensitizers and is approved in more than 40 countries
worldwide to improve cardiac function in patients with acute
heart failure (14). Although the loading dose of levosimendan
in this study is higher than recommended for the treatment of
TABLE 1. DIAPHRAGM CONTRACTILITY AND HEMODYNAMIC VARIABLES AT BASELINE AND AFTER LOADING1 BOLUS ADMINISTRATION
Variables
Placebo (n ¼ 13) Levosimendan (n ¼ 14)
Baseline After Loading 1 Bolus Administration Baseline After Loading 1 Bolus Administration
Diaphragm contractility*
Pditw, cm H2O 35 6 2
† 32 6 2‡ 30 6 2 31 6 2
CMAPdi, mV 1.3 6 0.2 1.3 6 0.2 1.0 6 0.1 1.1 6 0.1
Pdimax, cm H2O 130 6 8 122 6 7
‡ 123 6 11 120 6 8
EMGdimax, mV 76 6 9 81 6 10 77 6 8 74 6 10
Hemodynamic variablesx
MAP, mm Hg 92 6 2 89 6 4 90 6 3 86 6 4
HR, bpm 71 6 3 73 6 3 68 6 2 83 6 3‡
CO, L/min 4.5 6 1.3 4.6 6 0.4 6.2 6 0.7 7.0 6 0.7‡
Definition of abbreviations: CMAPdi ¼ compound muscle action potential of the diaphragm; CO ¼ cardiac output; EMGdimax ¼maximum electromyographic activity;
MAP ¼ mean arterial pressure; Pdimax ¼ maximum transdiaphragmatic pressure; Pditw ¼ twitch transdiaphragmatic pressure; HR ¼ heart rate.
* Pditw, CMAPdi, Pdimax, and EMGdimax were measured before the first loading task and after bolus administration of study medication.
yData are presented as mean 6 SEM.
z Significantly different from before study medication (P , 0.05).
xMAP, HR, and CO were measured directly before and after bolus administration. CO was measured only in n ¼ 2 (placebo group) and n ¼ 4 (levosimendan group).
Figure 2. (A) The compound muscle action potential of the diaphragm
(CMAPdi) and (B) twitch transdiaphragmatic pressure (Pditw) elicited by
cervical magnetic stimulation before (black line) and after the first load-
ing task (blue striped line) in a subject receiving placebo. In response to
equal diaphragm activation (i.e., equal CMAPdi), there is decreased con-
tractility after loaded breathing. Note the difference in scale of the x axis
between panels A and B.
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acute heart failure (14), the total dose of levosimendan admin-
istered is lower than used in clinical practice.
Calcium sensitization by levosimendan occurs through stabili-
zation of the interaction between calcium and the troponin com-
plex during muscle activation (17). Recently, we have shown that
levosimendan improves in vitro calcium sensitivity of human
diaphragm (skeletal) muscle fibers as well (12, 18). Improvement
in calcium sensitivity will affect contractile efficiency of the
diaphragm (19). In the current study, loaded breathing reduced
Pditw in placebo-treated subjects (Table 1; Figure 3), which is
consistent with previous data by Laghi and colleagues (20). How-
ever, levosimendan reversed the development of fatigue; Pditw
after loading in these subjects was not different from baseline.
Neuromechanical efficiency of the diaphragm during loaded
breathing, expressed as Pdi/EMGdi ratio, was enhanced by
21% after administration of levosimendan (Figure 5). A 21%
improvement in the ability to generate inspiratory pressure for
a given neural respiratory effort should be considered a clinically
relevant improvement in contractility. In vitro studies have shown
that impaired calcium sensitivity of force generation develops
during muscle loading and may contribute to contractile failure
(21). This is in line with the data from the current study that show
that levosimendan reverses the effects of diaphragm force loss
(Table 1; Figure 3).
Administration of levosimendan resulted in a downward shift
of the CFdi curve during loaded breathing (Figure E1). The
decrease in CFdi over time indicates the development of reduced
muscle fiber conduction velocity (see the online supplement for
details). Reduced muscle fiber conduction velocity is an in-
creased difficulty of muscle fiber action potentials to propagate
along the sarcolemma and into T tubuli (22). Therefore, the
downward shift in baseline CFdi in subjects receiving levosimen-
dan most likely reflects a baseline decrease in muscle fiber con-
duction velocity. These data are in line with the established
effects of levosimendan on KATP channel activation (15) and
with the finding that extracellular [K1] accumulation contributes
to reduced muscle fiber conduction velocity (23, 24). Because
administration of levosimendan improves neuromechanical effi-
ciency of the diaphragm by 21%, it is unlikely that extracellular
[K1] accumulation results in functional impairment of the dia-
phragm. Moreover, preserving a hyperpolarized sarcolemma by
activating KATP channels might play a myoprotective role under
conditions of metabolic stress (25).
Enhancing calcium sensitivity with levosimendan appears to
be a rational and effective approach to improve respiratory mus-
cle function, in particular in patients with imminent respiratory
failure.
Clinical Implications
Reduced force generation of the respiratory muscles has been
demonstrated in numerous disorders, includingCOPD, congestive
heart failure, pulmonary hypertension, and patients onmechanical
ventilation (1–7). There are no pharmacological interventions
available to improve respiratory muscle function.
Aubier and colleagues have previously shown that dopamine
(26) and aminophylline (27) improve contractility of the human
diaphragm, although the effects of aminophylline are controver-
sial (28). Neither dopamine nor aminophylline has been used in
clinical practice to optimize respiratory muscle function, probably
due to the small therapeutic window, the risk of severe side effects
(aminophylline, dopamine), and the very short half-life (dopa-
mine). Instead, the active levosimendan metabolite OR-1896 has
a half-life of 70 to 80 hours, resulting in clinical effect up to 1 week
after 24-hour infusion (29). More importantly, both aminophylline
and dopamine improve contractility by elevating intracellular cal-
cium concentration, resulting in an increased ATP utilization. As
discussed elsewhere (12), inorganic phosphate accumulation con-
tributes to the development of muscle fatigue and depresses cal-
cium sensitivity (30). In addition, elevated energy expenditure
increases CO2 production, requiring a higher level of ventilation.
This limits the clinical utility of these drugs for the improvement of
respiratory muscle function in patients with imminent ventilatory
failure. Rather, calcium sensitizers improve muscle contractility
without elevating energy expenditure (31). In addition, more effi-
cient breathing may hasten liberation from mechanical ventilation
(32). This may be important for patients with respiratory failure,
such as acute exacerbation of COPD. Of note, our previous in
vitro work showed that the effect of levosimendan is more pro-
found in type-1 diaphragm fibers than in type-2 fibers (12). Be-
cause a fiber type shift toward type-1 fibers is known to occur
in the diaphragm of patients with COPD (8) and congestive
heart failure (33), levosimendan treatment can potentially be
more effective in these patients than in healthy subjects. Accord-
ingly, the rationale for evaluating the effect of levosimendan on
respiratory muscle function in patients with respiratory failure
appears highly appropriate.
Experimental Model
The contractile performance of the diaphragm was evaluated
using magnetic stimulation and maximal inspiratory efforts.
Figure 3. Percentage change in transdiaphragmatic twitch pressure
(Pditw) from baseline after loading 1 bolus administration in the placebo
(closed squares) and levosimendan (open circles) group. Data are presented
as mean 6 SEM (placebo, n ¼ 13; levosimendan, n ¼ 14). *Significantly
different from baseline (P ¼ 0.01) and levosimendan group after loading1
bolus administration (P ¼ 0.01).
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Magnetic stimulation has a clear benefit over voluntary maneu-
vers because it is effort independent and highly reproducible
(34). Values for Pditw and Pdimax reported in our study are similar
o those reported by other groups for healthy subjects (20, 35).
Due to coincidence, baseline Pditw and CMAPdi amplitude were
lower (though insignificant) in the levosimendan group (Table 1),
suggesting these subjects were more difficult to stimulate. Cor-
recting for CMAPdi amplitude abolished the baseline difference
between the groups (data not shown).
To further evaluate the function of the diaphragm,wemeasured
neuromechanical efficiency of the diaphragm (Pdi/EMGdi) during
inspiratory loaded breathing. We found that diaphragm neuro-
mechanical efficiency at 40% of Pdimax was constant over time
and that CFdi decreased over time during loaded breathing, which
are in line with previous data from Sinderby and colleagues (36).
We also found that, despite evidence of twitch force loss, the dia-
phragm neuromechanical efficiency was not reduced in the pla-
cebo group during the second loaded breathing task. Thus, the
reductions in maximal contractility were not reflected in the
neuromechanical efficiency during submaximal contractions. Re-
gardless of the reason for this inconsistency, the double-blinded
randomized design of the study should ensure that the finding of
improved neuromechanical efficiency, which occurred only in the
levosimendan group, was not due to bias, carry-over effects, or
other subjective influences.
For an accurate physiological measurement of EMGdi and
CFdi during voluntary breathing, it is necessary to control for
changes in muscle-to-electrode distance, electrode positioning
with respect to the muscle fiber direction and location, influence
of cross-talk from other muscles (including the heart and the
esophagus), and electrode movement–induced artifacts. The
technology used to measure and process the EMGdi and CFdi
in our study minimizes these influences (37, 38).
It could be postulated that improved contractile function of
the diaphragm resulted from the cardiac inotropic effects of
levosimendan. However, subjects in the present study did
not have a medical history of cardiac disease, and the effect
of levosimendan on cardiac output was modest. Development
of Pditw occurs through a sharp anaerobic maneuver of the
diaphragm; therefore, it is unlikely that an improved cardiac
output (and oxygen delivery) would explain the restored dia-
phragm contractility with levosimendan. Moreover, levosi-
mendan improved efficiency already during unloaded
breathing and immediately at the start of the loading task,
which is unlikely to be the result of improved oxygen delivery
to the diaphragm
The dosage of levosimendan used in the current study was de-
rived from earlier studies in healthy subjects that demonstrated
limited side effects (39). This is in line with our study. Future
studies should evaluate the effects of lower doses of levosimen-
dan on respiratory muscle function in humans.
In conclusion, the present study demonstrates that the calcium
sensitizer levosimendan improves contractile function and neuro-
mechanical efficiency of the human diaphragm. These findings
suggest a new therapeutic approach for patients with acute respi-
ratory muscle dysfunction.
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Figure 5. Neuromechanical efficiency of the diaphragm
(Pdi/EMGdi) before, during (at 1, 3, 6, and 9 min) and after
the first and second loading task in the placebo (A) and
levosimendan (B) groups. Administration of levosimendan
resulted in an increase in diaphragm efficiency (P , 0.05)
during loaded and unloaded breathing, whereas placebo
had no effect on diaphragm efficiency. Data are presented
as mean 6 SEM (placebo, n ¼ 13; levosimendan, n ¼ 14).
Figure 4. Diaphragm electromyography (EMGdi) and transdiaphrag-
matic pressure (Pdi) during the first (black) and second loading task (blue)
in a subject receiving placebo (A and B) and levosimendan (C and D).
Subjects were asked to target 40% of Pdimax. In the subject receiving
placebo, there is no change in EMGdi (i.e., neural activation), whereas
the subject receiving levosimendan shows decreased neural activation
and thus increased neuromechanical efficiency of the diaphragm.
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